Cleveland Clinic Cancer Center (Taussig) Outcomes
Thoracic Oncology (Lung Cancer)
Lung Cancer Treatment
Taussig Cancer Institute's Thoracic Oncology Program offers patients with thoracic malignancies leading-edge, multidisciplinary care. In consultation with patients, collaborative teams of surgical, medical, and radiation oncologists tailor treatment plans to the needs of each patient. An active clinical research program provides patients with additional treatment options.
The Department of Radiation Oncology actively participates in Cleveland Clinic in-house protocols and is a full member of the NRG Oncology research organization. The department is among the leading institutions nationally for accrual of patients to multiple NRG Oncology clinical trials.
Five-Year Overall Survival of Patients With All Stagesᵃ of Non-Small Cell Lung Cancer (N= 7916)
2011-2021
ᵃAJCC stage I-IV small cell lung cancer
Five-Year Overall Survival of Patients With Non-Small Cell Lung Cancer by Stageᵃ (N = 7396)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage I (N = 2508) | 1941 | 1500 | 1048 | 726 | 450 |
| Stage II (N = 838) | 605 | 441 | 299 | 210 | 138 |
| Stage III (N = 1504) | 909 | 570 | 370 | 248 | 154 |
| Stage IV (N = 2546) | 971 | 475 | 245 | 152 | 92 |
ᵃAJCC stage I-IV non-small cell lung cancer
Local Control for Patients With Medically Inoperable Stage Iᵃ Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy (N = 1386)
2010-2020
| Time from SBRT | 1 Yr | 2 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|---|
| Local Control (Number of Patients) | 97.6 % (964) | 91.8% (615) | 90.5% (404) | 88.0% (172) | 82.1% (12) |
ᵃAJCC stage I non-small cell lung cancer
ᵇThere is no reference value for year 4
ᶜZheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-611
Overall Survival of Patients With Medically Inoperable Stage Iᵃ Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy (N = 1386)
2010-2020
| Time from SBRT | 1 Yr | 2 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|---|
| Overall Survival (Number of Patients) | 81.0% (1087) | 61.5% (751) | 47.8% (517) | 29.2% (237) | 7.5% (22) |
CC = Cleveland Clinic
ᵃAJCC stage I non-small cell lung cancer
ᵇThere is no reference value for years 2 and 4
ᶜZheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-611.
Five-Year Overall Survival of Patients With Stage IIIᵃ Non-Small Cell Lung Cancer Treated With Radiation (N= 934)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage IIIA (N = 626) | 422 | 297 | 194 | 141 | 95 |
| Stage IIIB (N = 308) | 184 | 105 | 72 | 40 | 28 |
ᵃAJCC stage III non-small cell lung cancer
Five-Year Overall Survival of Patients With All Stages of Small Cell Lung Cancerᵃ (N= 978)
2011-2021
ᵃAmerican Joint Committee on Cancer (AJCC) stage I-IV non-small cell lung cancer
Five-Year Overall Survival of Patients With Early Stageᵃ Small Cell Lung Cancer (N = 365)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage I (N = 76) | 60 | 39 | 33 | 23 | 16 |
| Stage II (N = 65) | 43 | 29 | 13 | 10 | 6 |
| Stage III (N = 224) | 137 | 74 | 47 | 34 | 19 |
ᵃAJCC stage I-III small cell lung cancer
